SEC Tracker
Get the app
KOD · XBRL financial data

Kodiak Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (KOD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development3647*30333232*44435045*4956
General and administrative1817*16151514*15131212*1111
Total operating expenses5563*46484746*59566257*6067
Operating income (loss)(55)(63)*(46)(48)(47)(46)*(59)(56)(62)(57)*(60)(67)
Interest income54*3332*2111*21
Interest expense00*0000*———year only——
Other income (expense)(0)(0)*(0)(0)(0)(0)*0(0)(0)(0)*(0)(0)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(50)(60)*(43)(45)(44)(44)*(57)(54)(61)(57)*(58)(66)
Earnings per share, basic USD per share(0.95)(1.13)*(0.82)(0.86)(0.84)(0.84)*(1.09)(1.03)(1.16)(1.04)*(0.94)(1.05)
Earnings per share, diluted USD per share(0.95)(1.13)*(0.82)(0.86)(0.84)(0.84)*(1.09)(1.03)(1.16)(1.04)*(0.94)(1.05)
Weighted average shares, basic millions of shares5252*53535353*53535354*6263
Weighted average shares, diluted millions of shares5252*53535353*53535354*6263

Balance sheet

CSV

Fiscal quarters (KOD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents34628624621919816813910472210170126
Marketable securities00——————————
Prepaid and other current assets546554444565
Total current assets35128925222520217214310876215175131
Property and equipment, net125120116111107102989389858278
Right-of-use asset565553514947424139373432
Total assets548479435402373336298257218352306257
Accounts payable391422347510131113
Accrued liabilities23181391111131520212730
Total current liabilities714225212426313142465053
Lease liability, non-current747269666360575450474443
Total liabilities245214194187187185189186194194194196
Accumulated deficit(1,093)(1,153)(1,196)(1,241)(1,285)(1,329)(1,386)(1,441)(1,502)(1,559)(1,617)(1,683)
Total stockholders' equity302266241215185150109702415711261
Total liabilities and equity548479435402373336298257218352306257
Common shares outstanding (cover page) millions of shares525353535353535353626363

Cash flows

CSV

Fiscal quarters (KOD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(50)(60)*(43)(45)(44)(44)*(57)(54)(61)(57)*(58)(66)
Stock-based compensation14*23*1818*15*9*1616*14*13*1212*
Net cash from operating activities(33)*(32)*(40)(26)*(21)*(30)*(29)(35)*(33)*(39)*(40)(46)*
Purchases of property and equipment0*27*00*0*0*00*0*0*10*
Net cash from investing activities(0)*(28)*(0)(0)*(0)*(0)*(0)(0)*(0)*(0)*(1)(0)*
Net cash from financing activities(0)*(0)*00*0*0*00*1*177*13*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Kodiak Sciences126not reported(46)*62.8M2.7 quarters 10-QJun 30, 2026
Alector603.3(34)*111.7M5.1 quarters 10-QJun 30, 2026
Skye Bioscience8.1not reported(7.1)*35.4M1.4 quarters 10-QJun 30, 2026
Protalix BioTherapeutics2720(10)*80.6M2.6 quarters 10-QJun 30, 2026
Fate Therapeutics322.1(23)119.8M6.6 quarters 10-QJun 30, 2026
Caribou Biosciences261.5(23)*107.2M4.9 quarters 10-QJun 30, 2026
Protara Therapeutics17not reported(15)*59.1M9.3 quarters 10-QJun 30, 2026
TuHURA Biosciences1not reported(8.6)*63.7M0.1 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals3314(10)*29.1M19.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.